FOR SALE: State-of-the-Art cGMP-Qualified Solid Dosage Development and Manufacturing Facility
(Thomson Reuters ONE) -
The 100,000+ sq.-ft. facility is located on Long Island, less than 50 miles from
New York City.
COMMACK, NY, July 13, 2017 (GLOBE NEWSWIRE) -- A spacious, technologically
advanced facility, conveniently located within an area of robust pharmaceutical
initiatives, is now available for cGMP activities, from formulation development
to mid-size commercial production. Ropack Pharma Solutions (RPS) has made the
strategic decision to market and sell its 103,530-sq-ft pharmaceutical and
research facility on a 10.75-acre plot at 49 Mall Drive, Commack, New York.
The well-maintained facility has benefited from $50M in capital investments in
the past 10 years. It houses 16 process development and commercial manufacturing
suites as well as full-fit-out analytical laboratories. This facility has fully
validated HVACs, temperature- and humidity-controlled production suites, USP
water system, compressed air, laboratories, cGMP-qualified manufacturing clean
rooms and warehouses. Complete equipment train and lab devices allow the
capacity to perform a wide range of cGMP activities.
"We operated in this facility with the belief that advanced technology brings
advanced results," said Yves Massicotte, President and CEO of RPS. "We have
applied this principle in keeping the labs pristine and production suites
equipped, fully commissioned utility systems and technology from the most-
respected names in the industry to meet cGMP requirements."
With an excellent regulatory history; DEA Schedule II-V license; up to 40,000
sq. ft. of warehouse expansion possible on available land; and immediate, easy
freeway access (I-495), the 49 Mall Drive location has the capacity, technology
and amenities to meet the most exacting requirements.
Interested parties should contact Yves Massicotte for more information regarding
an acquisition of this Commack, New York-based solid dosage development and
manufacturing facility. For more information
visit http://www.ropack.com/2017/06/13/available/
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/0628c545-bf6d-40ab-b9cb-
203097df7bea
Attachments:
A photo accompanying this announcement is available
at http://www.globenewswire.com/NewsRoom/AttachmentNg/0200cfa6-
1881-4b51-956d-98261484ec5d
Yves Massicotte, President and CEO
Ropack Pharma Solutions
1-888-353-7090, ext. 2271
josee.leblanc(at)ropack.com
Josee LeBlanc, Assistant to the President and CEO
Ropack Pharma Solutions
1-888-353-7090, ext. 2271
josee.leblanc(at)ropack.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ropack Pharma Solutions via GlobeNewswire
Datum: 13.07.2017 - 20:52 Uhr
Sprache: Deutsch
News-ID 552390
Anzahl Zeichen: 3246
contact information:
Town:
Anjou
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 161 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"FOR SALE: State-of-the-Art cGMP-Qualified Solid Dosage Development and Manufacturing Facility"
steht unter der journalistisch-redaktionellen Verantwortung von
Ropack Pharma Solutions (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
